Bayer's Finerenone Shows Kidney and Cardiovascular Benefits in Hypertensive CKD Subgroup
New FIND-CKD data highlight finerenone’s potential to slow kidney disease progression and reduce cardiovascular-kidney risks in patients with hypertensive nephropathy.
Positive Results | 01/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy